Apimeds Pharmaceuticals US IncAPUS
Price$5.00

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$35.1MTTM through 31 Mar 2026

Margins

Current
Gross Margin0.0%

Returns

-27.7%ROE
-24.8%ROA

Balance Sheet Health

Debt / Equity0.07x
Net Debt$7.4M
Cash & Equivalents$979.5K

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Segment$00.0%
View details

The company expects to continue incurring substantial losses as it advances its clinical trials and seeks FDA approval.

Digital Asset Segment$0
View details

Subject to high volatility from cryptocurrency price fluctuations, primarily Bitcoin, Tether, and NILA tokens.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.